Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.70 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.70 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.64 |
| ▸ | RAF1 | P04049 | 1/20 | 0.51 |
| ▸ | BRAF | P15056 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | CRHBP | P24387 | 1/20 | 0.47 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29762330 | 1.00 | MAPT (0.70) | MAPTCYP1A2CYP2D6KMT2ARAF1 | |
| SCHEMBL856718 | 0.90 | MAPT (0.61) | MAPTCYP1A2CYP2D6KMT2ARAF1 | |
| SCHEMBL21158324 | 0.89 | MAPT (0.57) | MAPTCYP1A2CYP2D6KMT2ARAF1 | |
| SCHEMBL855348 | 0.84 | MAPT (0.68) | MAPTCYP1A2CYP2D6KMT2ARAF1 | |
| SCHEMBL17859942 | 0.83 | CYP1A2 (0.54) | MAPTCYP1A2CYP2D6KMT2ARAF1 | |
| SCHEMBL1748520 | 0.82 | CYP1A2 (0.47) | MAPTCYP1A2CYP2D6KMT2ACRHBP | |
| SCHEMBL2771738 | 0.82 | CYP1A2 (0.47) | MAPTCYP1A2CYP2D6KMT2ACRHBP | |
| SCHEMBL13989245 | 0.82 | MAPT (0.66) | MAPTCYP1A2CYP2D6KMT2ARAF1 | |
| SCHEMBL1028538 | 0.82 | CYP1A2 (1.00) | MAPTCYP1A2CYP2D6KMT2ARAF1 | |
| SCHEMBL30353341 | 0.82 | CYP1A2 (0.66) | MAPTCYP1A2CYP2D6KMT2ARAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 265 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113683596-B | Pyrimidine tankyrase 2 inhibitor and preparation method and application thereof | 上海应用技术大学 | 2023-02-10 | — | — | CN | claimed |
| CN-113683596-A | Pyrimidine tankyrase 2 inhibitor and preparation method and application thereof | 上海应用技术大学 | 2021-11-23 | — | — | CN | claimed |
| EP-4696326-A1 | PIKFYVE PROTEIN KINASE DEGRADATION AGENT AND USE THEREOF | SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, CHINESE ACADEMY OF SCIENCES (CN) | 2026-02-18 | — | — | EP | disclosed |
| US-12497407-B2 | Treatment of skin disorders | TORQUR AG (CH) | 2025-12-16 | — | — | US | disclosed |
| US-12312336-B2 | Inhibitors of RAF kinases | Pierre Fabre Médicament (FR) | 2025-05-27 | — | — | US | disclosed |
| US-20240382496-A1 | TREATMENT OF SKIN LESIONS | TORQUR AG (CH) | 2024-11-21 | — | — | US | disclosed |
| US-20240368184-A1 | PIKfyve Inhibitors | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2024-11-07 | — | — | US | disclosed |
| US-20240343718-A1 | TREATMENT OF NEUROLOGICAL DISORDERS | TORQUR AG (CH) | 2024-10-17 | — | — | US | disclosed |
| WO-2024213160-A1 | PIKFYVE PROTEIN KINASE DEGRADATION AGENT AND USE THEREOF | 中国科学院上海有机化学研究所 | 2024-10-17 | — | — | WO | disclosed |
| US-12030896-B2 | PIKfyve inhibitors | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2024-07-09 | — | — | US | disclosed |
| US-12030896-B2 | PIKfyve inhibitors | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2024-07-09 | — | — | US | disclosed |
| WO-2005007646-A1 | SUBSTITUTED HETEROCYCLIC DIARYLAMINE ANALOGUES | NEUROGEN CORPORATION (US) | 2005-01-27 | — | — | WO | disclosed |
| WO-2005000404-A2 | HETEROCYCLIC COMPOUNDS FOR PREVENTING AND TREATING DISORDERS ASSOCIATED WITH EXCESSIVE BONE LOSS | SYNTA PHARMACEUTICALS, CORP. (US) | 2005-01-06 | — | — | WO | disclosed |
| EP-1458687-A2 | PYRIMIDINE COMPOUNDS | Synta Pharmaceuticals Corporation (US) | 2004-09-22 | — | — | EP | disclosed |
| WO-2004024810-A2 | STABILLIZATION OF ORGANIC MATERIALS | CIBA, SPECIALTY CHEMICALS HOLDING INC. (CH) | 2004-03-25 | — | — | WO | disclosed |
| US-20040048873-A1 | Pyrimidine compounds | SYNTA PHARMACEUTICALS CORP., A DELAWARE CORPORATIO | 2004-03-11 | — | — | US | disclosed |
| US-6693097-B2 | Pyrimidine compounds | SYNTA PHARMACEUTICALS CORP. | 2004-02-17 | — | — | US | disclosed |
| US-20040024206-A1 | Pyrimidine compounds | MADRIGAL PHARMACEUTICALS, INC. | 2004-02-05 | — | — | US | disclosed |
| US-20030139403-A1 | Pyrimidine compounds | SHIONOGI BIORESEARCH CORP. | 2003-07-24 | — | — | US | disclosed |
| WO-2003047516-A2 | PYRIMIDINE COMPOUNDS | SYNTA PHARMACEUTICALS CORPORATION (US) | 2003-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12030896-B2 | PIKfyve inhibitors | PIKFYVE, PIP4K2B, PIP4K2A | MAPT 3914/4885CYP1A2 3815/4885CYP2D6 3982/4885 |
| US-20240382496-A1 | TREATMENT OF SKIN LESIONS | C1R, C3AR1, CXCR3 | MAPT 2395/4885CYP1A2 303/4885CYP2D6 348/4885 |
| US-20240343718-A1 | TREATMENT OF NEUROLOGICAL DISORDERS | CHRM2, CHRM1, C1R | MAPT 261/4885CYP1A2 136/4885CYP2D6 146/4885 |
| US-20240368184-A1 | PIKfyve Inhibitors | PIKFYVE, PIP4K2B, PIP4K2A | MAPT 3914/4885CYP1A2 3815/4885CYP2D6 3982/4885 |
| US-12497407-B2 | Treatment of skin disorders | RXFP3, CCR3, CBR3 | MAPT 2061/4885CYP1A2 405/4885CYP2D6 638/4885 |
| US-20030139403-A1 | Pyrimidine compounds | CBR1, CBR3, CCNO | MAPT 4042/4885CYP1A2 579/4885CYP2D6 171/4885 |
| US-20040024206-A1 | Pyrimidine compounds | CBR1, CCR4, CNR1 | MAPT 2986/4885CYP1A2 469/4885CYP2D6 245/4885 |
| US-12312336-B2 | Inhibitors of RAF kinases | BRAF, RAF1, ARAF | MAPT 2859/4885CYP1A2 4302/4885CYP2D6 4339/4885 |
| US-20040048873-A1 | Pyrimidine compounds | CBR1, CBR3, CCNO | MAPT 4185/4885CYP1A2 684/4885CYP2D6 207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.